The Scientist discusses retraction by the Lancet of a Harvard paper on stem cells

from The Scientist:Update (March 15): The Lancet sent The Scientist the retraction notice, which states that the data from Harvard “cannot be held to be reliable.” The editors note that they believe the clinical work conducted in Louisville was done “in good faith.”Since 2014, a paper in The Lancet describing the results of a clinical trial using supposed cardiac stem cells has sat with an editors’ expression of concern looming over it. Now, the journal has retracted the paper—the 16th retraction for Piero Anversa, formerly of Harvard Medical School and Brigham and Women’s Hospital.The Scientist could not locate a retraction notice, and the press office at The Lancet did not immediately respond to a request for information. (We sent the message after business hours in the UK, and will update this post once we hear back.)In October, Harvard Medical School and Brigham and Women’s Hospital determined that 31 papers from the Anversa…

Read more detail on Recent Intellectual Property Law posts –

Related news:

This entry was posted in Intellectual Property and tagged , , , , , , , . Bookmark the permalink.

Leave a Reply